BioSpace News Archive

Insmed Incorporated today announced three strategic financings resulting in aggregate gross proceeds of $775 million.

Telesis Bio today announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp ® Digital-to-Biological Converter™ (DBC) instrument for fully automated manufacturing of on-demand CRISPR-Cas9 guide RNA (gRNA) for genome editing.

Aspen Neuroscience, Inc. announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company’s executive team.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces the presentation of two posters detailing the Company’s RAS-Targeted platform at the National Cancer Institute-sponsored Fourth RAS Initiative Symposium to be held October 17-19, 2022 at The Advanced Technology Research Facility of the National Cancer Institute in Frederick, Maryland.

Heart Test Laboratories, Inc. d/b/a HeartSciences reports that the American Medical Association has issued new industry-first Category III Current Procedural Terminology codes for novel AI assistive algorithmic ECG risk assessment for cardiac dysfunction.

Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”) today announced that it completed an IRB-approved human study measuring blood pressure that utilized its non-invasive, cuffless biosensing device, currently under development.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”) announced today that the Company will be hosting booths this week at IDWeek 2022 in Washington, D.C., and at Asia Health/Medlab Asia in Bangkok, Thailand.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) and its wholly-owned subsidiary, PreCerv Inc., are pleased to announce the commencement of PreCerv Inc.'s study of NCP-01.

The global medical device contract manufacturing market size accounted for 72.89 billion in 2022 and would grow to USD 167.34 billion by 2030, with a remarkable CAGR of 10.9% between 2022 and 2030.

M3 Wake Research, a leading fully integrated network of clinical research sites and one of North America’s largest providers of Phase I-IV clinical trials, welcomes a new Chief Operations Officer, Lynn King.